Literature DB >> 16617127

Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature.

Anuradha Dhanasekaran1, Rula Al-Saghir, Bernardo Lopez, Daling Zhu, David D Gutterman, Elizabeth R Jacobs, Meetha Medhora.   

Abstract

Epoxyeicosatrienoic acids (EETs) are cytochrome P-450 (CYP) metabolites synthesized from the essential fatty acid arachidonic acid to generate four regioisomers, 14,15-, 11,12-, 8,9-, and 5,6-EET. Cultured human coronary artery endothelial cells (HCAECs) contain endogenous EETs that are increased by stimulation with physiological agonists such as bradykinin. Because EETs are known to modulate a number of vascular functions, including angiogenesis, we tested each of the four regioisomers to characterize their effects on survival and apoptosis of HCAECs and cultured human lung microvascular endothelial cells (HLMVECs). A single application of physiologically relevant concentration of 14,15-, 11,12-, and 8,9-EET but not 5,6-EET (0.75-300 nM) promoted concentration-dependent increase in cell survival of HLMVECs and HCAECs after removal of serum. The lipids also protected the same cells from death via the intrinsic, as well as extrinsic, pathways of apoptosis. EETs did not increase intracellular calcium concentration ([Ca2+]i) or phosphorylate mitogen-activated protein kinase p44/42 when applied to these cells, and their protective action was attenuated by the phosphotidylinositol-3 kinase inhibitor wortmannin (10 microM) but not the cyclooxygenase inhibitor indomethacin (20 microM). Our results demonstrate for the first time the capacity of EETs to enhance human endothelial cell survival by inhibiting both the intrinsic, as well as extrinsic, pathways of apoptosis, an important underlying mechanism that may promote angiogenesis and endothelial survival during atherosclerosis and related cardiovascular ailments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617127     DOI: 10.1152/ajpheart.00953.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  32 in total

1.  Soluble epoxide hydrolase: sex differences and role in endothelial cell survival.

Authors:  Nandita C Gupta; Catherine M Davis; Jonathan W Nelson; Jennifer M Young; Nabil J Alkayed
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

2.  Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.

Authors:  Tracy C Delozier; Grace E Kissling; Sherry J Coulter; Diana Dai; Julie F Foley; J Alyce Bradbury; Elizabeth Murphy; Charles Steenbergen; Darryl C Zeldin; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2007-01-12       Impact factor: 3.922

3.  Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model.

Authors:  Jun-Yan Liu; Hong Qiu; Christophe Morisseau; Sung Hee Hwang; Hsing-Ju Tsai; Arzu Ulu; Nipavan Chiamvimonvat; Bruce D Hammock
Journal:  Toxicol Appl Pharmacol       Date:  2011-06-25       Impact factor: 4.219

Review 4.  Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.

Authors:  Christophe Morisseau; Bruce D Hammock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

5.  Epoxyeicosatrienoic acid (EET)-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids (EHETs) formed from COX-2.

Authors:  Amy A Rand; Anita Rajamani; Sean D Kodani; Todd R Harris; Lukas Schlatt; Bodgan Barnych; Anthony G Passerini; Bruce D Hammock
Journal:  J Lipid Res       Date:  2019-10-22       Impact factor: 5.922

Review 6.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

7.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01

8.  20-HETE increases superoxide production and activates NAPDH oxidase in pulmonary artery endothelial cells.

Authors:  Meetha Medhora; Yuenmu Chen; Stephanie Gruenloh; Daniel Harland; Sreedhar Bodiga; Jacek Zielonka; Debebe Gebremedhin; Ying Gao; John R Falck; Siddam Anjaiah; Elizabeth R Jacobs
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-02-22       Impact factor: 5.464

9.  Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Authors:  Garrett J Gross; Kathryn M Gauthier; Jeannine Moore; John R Falck; Bruce D Hammock; William B Campbell; Kasem Nithipatikom
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-04-25       Impact factor: 4.733

10.  An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis.

Authors:  Sergey Y Cheranov; Manjula Karpurapu; Dong Wang; Baolin Zhang; Richard C Venema; Gadiparthi N Rao
Journal:  Blood       Date:  2008-04-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.